Progress towards ending the AIDS epidemic by 2030 is variable across the region, and most countries in Europe and Central Asia are currently far from achieving the 2025 targets.
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
For 2021, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 33 527 tuberculosis (TB) cases (7.4 per 100 000 population).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.